FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0104 | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| DDECEDEL CIVI CEENTEN | | | | of Event Requir ent (Month/Day/ 2021 | | 3. Issuer Name and Ticker or Trading Symbol Xeris Biopharma Holdings, Inc. [XERS] | | | | | | | |
|---|--|--|---------------------|--|---|---|---|----------------------|---|---|--|---|--|
| (Last) C/O XERIS BIOI 180 N. LASALLI (Street) CHICAGO (City) | | * | _ | | | | onship of Reporting Person(s) to Iss all applicable) Director Officer (give title below) Chief Scientific O | 10% Owr Other (sp | | pelow) | | vidual or Joint/Grou Form filed by C | Original Filed (Month/Day/Year) p Filing (Check Applicable Line) ne Reporting Person tore than One Reporting Person |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | | | | | | |
| | | | | | 2. Amount Owned (In | t of Securities Beneficially str. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | | | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | |
| Expira | | 2. Date Exerc Expiration Da (Month/Day/) | | | 3. Title and Amount of Securities Underlyi Security (Instr. 4) | | C | | ion ise | 5. Ownership Form: Direct (D) or Indirect (I) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| | | | Date Exercisable | Expiration Date | | Title | | | Price of Derivativ Security | re | (Instr. 5) | | |

Explanation of Responses:

Remarks:

No securities are beneficially owned.

/s/ Beth Hecht, as Attorney-in-Fact

10/05/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Power of Attorney

Know all by these presents that the undersigned hereby constitutes and appoints each of Paul R. Edick, Beth Hecht, Joseph Theis and Stephanie I

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Xeris Biopharma Holdings, Inc., a Delaware co
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of beautiful takes and the contraction of the c

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of October, 2021.

/s/ Steven Prestrelski Name: Steven Prestrelski